Hormonal
Biological adaptations to energy-restricted weight loss—including reduced leptin/insulin, increased hypothalamic NPY/AgRP, and suppressed energy expenditure—create a persistent drive for weight regain that actively counteracts behavioral efforts to maintain weight loss.
If you have lost weight, expect your body to fight back. Your hormones (leptin, insulin) and brain signals (hunger peptides) will change to promote weight regain. This is not a failure of willpower but a biological defense mechanism. Long-term success requires strategies that are 'comprehensive, persistent, and redundant' to counter these specific biological adaptations, rather than relying on willpower alone.
The preponderance of evidence would suggest that the biological response to weight loss involves comprehensive, persistent, and redundant adaptations in energy homeostasis and that these adaptations underlie the high recidivism rate in obesity therapeutics.
Why this rating
This is a comprehensive review of multiple human and animal studies confirming consistent biological adaptations.
Source
Biology's response to dieting: the impetus for weight regain
Paul S. MacLean et al. · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · 2011
DOI 10.1152/ajpregu.00755.2010
More from this paper
- Adiposity signals (leptin and insulin) decline disproportionately to fat mass loss because smaller adipocytes secrete less leptin and are more insulin-sensitive, creating a persistent 'energy depletion' signal even when fat mass is stable.Strong
- Energy expenditure declines after weight loss due to both reduced body mass (less tissue to maintain and move) and enhanced metabolic efficiency (regulated by homeostatic feedback loops), creating a persistent energy gap.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →